Published in MAGMA on September 21, 2012
Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. Am J Nucl Med Mol Imaging (2013) 1.15
Competitive advantage of PET/MRI. Eur J Radiol (2013) 0.98
Review of fluorescence guided surgery visualization and overlay techniques. Biomed Opt Express (2015) 0.97
Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging (2015) 0.95
Attenuation correction for flexible magnetic resonance coils in combined magnetic resonance/positron emission tomography imaging. Invest Radiol (2014) 0.84
Does the novel integrated PET/MRI offer the same diagnostic performance as PET/CT for oncological indications? PLoS One (2014) 0.84
Impact of incorrect tissue classification in Dixon-based MR-AC: fat-water tissue inversion. EJNMMI Phys (2014) 0.83
Metal artifact reduction in patients with dental implants using multispectral three-dimensional data acquisition for hybrid PET/MRI. EJNMMI Phys (2014) 0.83
Characterization of the impact to PET quantification and image quality of an anterior array surface coil for PET/MR imaging. MAGMA (2013) 0.82
Attenuation correction in emission tomography using the emission data-A review. Med Phys (2016) 0.79
Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET/MR. EJNMMI Phys (2015) 0.78
Coronary Artery PET/MR Imaging: Feasibility, Limitations, and Solutions. JACC Cardiovasc Imaging (2017) 0.78
Evaluation of diagnostic performance of whole-body simultaneous PET/MRI in pediatric lymphoma. Pediatr Radiol (2016) 0.77
Potential influence of Gadolinium contrast on image segmentation in MR-based attenuation correction with Dixon sequences in whole-body 18F-FDG PET/MR. MAGMA (2015) 0.77
MR/PET or PET/MRI: does it matter? MAGMA (2013) 0.77
Impact of MR-safe headphones on PET attenuation in combined PET/MRI scans. EJNMMI Res (2016) 0.76
Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. EJNMMI Phys (2015) 0.75
Automatic correction of dental artifacts in PET/MRI. J Med Imaging (Bellingham) (2015) 0.75
Feasibility of carotid artery PET/MRI in psoriasis patients. Am J Nucl Med Mol Imaging (2016) 0.75
Quantitative myocardial blood flow imaging with integrated time-of-flight PET-MR. EJNMMI Phys (2017) 0.75
MLAA-based attenuation correction of flexible hardware components in hybrid PET/MR imaging. EJNMMI Phys (2017) 0.75
A combined PET/CT scanner for clinical oncology. J Nucl Med (2000) 4.99
Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med (2011) 2.98
Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med (2009) 2.65
X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med (2003) 2.65
Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med (2007) 2.59
MRI-based attenuation correction for hybrid PET/MRI systems: a 4-class tissue segmentation technique using a combined ultrashort-echo-time/Dixon MRI sequence. J Nucl Med (2012) 1.92
Multimodality imaging of structure and function. Phys Med Biol (2008) 1.74
MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods. J Nucl Med (2011) 1.61
Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data. Eur J Nucl Med Mol Imaging (2010) 1.59
Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging (2011) 1.54
Simultaneous maximum a posteriori reconstruction of attenuation and activity distributions from emission sinograms. IEEE Trans Med Imaging (1999) 1.42
Quantitation in positron emission computed tomography: 2. Effects of inaccurate attenuation correction. J Comput Assist Tomogr (1979) 1.41
PET/MR imaging of bone lesions--implications for PET quantification from imperfect attenuation correction. Eur J Nucl Med Mol Imaging (2012) 1.34
Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med (2004) 1.27
The effect of errors in segmented attenuation maps on PET quantification. Med Phys (2011) 1.23
The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond. Insights Imaging (2011) 1.13
Latest advances in molecular imaging instrumentation. J Nucl Med (2008) 1.13
Cost considerations regarding an integrated CT-PET system. Eur Radiol (2000) 1.07
Nonrigid PET motion compensation in the lower abdomen using simultaneous tagged-MRI and PET imaging. Med Phys (2011) 1.02
Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective. MAGMA (2012) 0.98
The effect of limited MR field of view in MR/PET attenuation correction. Med Phys (2010) 0.96
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Preoperative staging of lung cancer with combined PET-CT. N Engl J Med (2009) 7.38
Analogical reasoning in handling emerging technologies: the case of umbilical cord blood biobanking. Am J Bioeth (2006) 5.21
Evidence for a vascular factor in migraine. Ann Neurol (2011) 2.93
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med (2003) 2.65
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2010) 2.48
Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. Thorax (2010) 2.44
Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging (2009) 2.28
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol (2004) 2.23
Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med (2005) 2.17
Are health technology assessments a reliable tool in th analysis of the clinical value of PET in oncology? Who audits the auditors? Eur J Nucl Med Mol Imaging (2003) 2.08
MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage (2004) 2.07
The reaction index and positivity ratio revisited. Contact Dermatitis (2008) 1.99
Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology (2003) 1.90
Nicotine conjugate vaccine: is there a right to a smoking future? J Med Ethics (2004) 1.79
Extending human lifespan and the precautionary paradox. J Med Philos (2002) 1.72
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol (2009) 1.71
Fever of unknown origin: prospective comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. Eur J Nucl Med Mol Imaging (2004) 1.63
Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial. Eur J Nucl Med Mol Imaging (2011) 1.63
MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation- and atlas-based methods. J Nucl Med (2011) 1.61
Time-of-flight PET/CT using low-activity protocols: potential implications for cancer therapy monitoring. Eur J Nucl Med Mol Imaging (2010) 1.58
Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun (2010) 1.57
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. J Nucl Med (2006) 1.55
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med (2004) 1.51
Early clinical experience and impact of 18F-FDG PET. Nucl Med Commun (2005) 1.46
HIV infection and arterial inflammation assessed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET): a prospective cross-sectional study. J Nucl Cardiol (2014) 1.46
Clinically feasible reconstruction of 3D whole-body PET/CT data using blurred anatomical labels. Phys Med Biol (2002) 1.44
Is conflict of interest in our best interest? Eur J Nucl Med Mol Imaging (2010) 1.44
Ethics in sports medicine. BMJ (2009) 1.41
Measurement of brain perfusion, blood volume, and blood-brain barrier permeability, using dynamic contrast-enhanced T(1)-weighted MRI at 3 tesla. Magn Reson Med (2009) 1.40
[Diagnostic imaging of cancer]. Ugeskr Laeger (2002) 1.39
An optimized conditional suicide switch using doxycycline-dependent expression of human tBid. Cancer Biol Ther (2005) 1.39
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood (2008) 1.38
PET/CT scanners: a hardware approach to image fusion. Semin Nucl Med (2003) 1.32
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res (2008) 1.30
The relationship between cerebral blood flow and volume in humans. Neuroimage (2005) 1.29
Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA (2006) 1.29
Accountability for reasonableness: opening the black box of process. Health Care Anal (2005) 1.28
Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neuroimage (2013) 1.28
Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med (2010) 1.27
Preclinical safety assessment of the 5-HT2A receptor agonist PET radioligand [ 11C]Cimbi-36. Mol Imaging Biol (2013) 1.25
Five systems of psychiatric classification for preschool children: do differences in validity, usefulness and reliability make for competitive or complimentary constellations? Child Psychiatry Hum Dev (2008) 1.23
Reducing plasma membrane sphingomyelin increases insulin sensitivity. Mol Cell Biol (2011) 1.20
Unchanged cerebral blood flow and oxidative metabolism after acclimatization to high altitude. J Cereb Blood Flow Metab (2002) 1.16
Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. Am J Nucl Med Mol Imaging (2013) 1.15
Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. Neuroimage (2004) 1.14
64Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials (2011) 1.13
The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond. Insights Imaging (2011) 1.13
A combined PET/CT scanner: the path to true image fusion. Br J Radiol (2002) 1.12
Summary report of the First International Workshop on PET/MR imaging, March 19-23, 2012, Tübingen, Germany. Mol Imaging Biol (2013) 1.10
The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol (2007) 1.10
Comparison of suction catheter versus forceps biopsy for sampling of solitary pulmonary nodules guided by electromagnetic navigational bronchoscopy. Respiration (2009) 1.07
Surveys of current status in biomedical science grant review: funding organisations' and grant reviewers' perspectives. BMC Med (2010) 1.07
Whole-body hybrid PET/MRI: ready for clinical use? Eur J Nucl Med Mol Imaging (2011) 1.07
Positron emission tomography/computed tomography--imaging protocols, artifacts, and pitfalls. Mol Imaging Biol (2004) 1.07
Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging (2011) 1.06
Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One (2010) 1.06
Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology (2012) 1.05
Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiother Oncol (2011) 1.04
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. BMC Cancer (2013) 1.03
How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. Eur J Nucl Med Mol Imaging (2006) 1.03
A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage (2004) 1.03
Clinical evaluation of PET image reconstruction using a spatial resolution model. Eur J Radiol (2012) 1.02
Methods for motion correction evaluation using 18F-FDG human brain scans on a high-resolution PET scanner. J Nucl Med (2012) 1.02
Curriculum for education and training of medical physicists in nuclear medicine: recommendations from the EANM Physics Committee, the EANM Dosimetry Committee and EFOMP. Phys Med (2012) 1.02
TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging (2007) 1.02
18FDG PET and ultrasound echolucency in carotid artery plaques. JACC Cardiovasc Imaging (2010) 1.02
Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J Immunol (2003) 1.01
Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology (2004) 1.01
Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging (2004) 1.00
Ethical endgames: broad consent for narrow interests; open consent for closed minds. Camb Q Healthc Ethics (2011) 0.99
PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol (2013) 0.99
Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med (2012) 0.99
Should we presume moral turpitude in our children?--small children and consent to medical research. Theor Med Bioeth (2003) 0.99
Changes to bodily appearance: the aesthetics of deliberate intervention. Med Humanit (2000) 0.99
High tumor uptake of (64)Cu: implications for molecular imaging of tumor characteristics with copper-based PET tracers. Nucl Med Biol (2013) 0.99
"Central command" and insular activation during attempted foot lifting in paraplegic humans. Hum Brain Mapp (2005) 0.98
Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab (2003) 0.98
Milgram and Tuskegee--paradigm research projects in bioethics. Health Care Anal (2003) 0.97
Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scand Cardiovasc J (2011) 0.97
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol (2007) 0.96
Genetic testing and sports medicine ethics. Sports Med (2009) 0.96
PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging. Am J Nucl Med Mol Imaging (2012) 0.96
To nudge or not to nudge: cancer screening programmes and the limits of libertarian paternalism. J Epidemiol Community Health (2012) 0.96
Subjective perception of radiation risk. J Nucl Med (2011) 0.95
Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol (2005) 0.95